Drug Profile
ONO 7579
Alternative Names: ONO-7579Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 09 Feb 2018 Ono Pharmaceutical terminates a phase I/II trial for commercial reasons for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA and United Kingdom (PO) (NCT03182257) (EudraCT2016-004987-21; NCT03182257)
- 12 Jul 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03182257)
- 19 May 2017 Ono Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in United Kingdom (PO) (NCT03182257)